Regenxbio (RGNX) Asset Writedowns and Impairment (2014 - 2024)
Regenxbio's (RGNX) quarterly Asset Writedowns and Impairment came in at $700000.0 in Q1 2024, up 34900.0% quarter-over-quarter from $2000.0 in Q4 2014.
Regenxbio (RGNX) Asset Writedowns and Impairment (2014 - 2024) Analysis & Trends
Regenxbio's Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $700000.0 for Q1 2024.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $700000.0 in Q1 2024; TTM through Dec 2024 was $700000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $2.1 million, changed N/A from the prior year.
- Asset Writedowns and Impairment advanced to $700000.0 in Q1 2024 per RGNX's latest filing, from $2000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $700000.0 in Q1 2024 and bottomed at $700000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn |
| 10 | Regenxbio | 504.90 Mn | 274.83 Mn | 21.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 700,000.00 |
| Mar 31, 2024 | 700,000.00 |
| Dec 31, 2014 | 2,000.00 |
| Dec 31, 2014 | 2,000.00 |